Our RNAseq analysis revealed consistent patterns of dysregulation for these biomarkers across all cancer stages, from Stage I to Stage IV, highlighting three of them: fibronectin 1 (FN1), coagulation factor V (F5), and thrombospondin 1 (THBS1). This evidence concerns the gene F5 and cancer.